Key result
Surgical and transcatheter mitral valve repair in octogenarians demonstrated in-hospital mortality rates of 2.6% and 1.4%, and 30-day mortality rates of 7.8% and 3.3%, respectively.
Why the study?
Octogenarians with mitral regurgitation are often denied mitral valve repair surgery due to concerns regarding operative mortality and postoperative morbidity.
Does surgical or transcatheter mitral valve repair have acceptable mortality and morbidity rates in octogenarians?
Systematic Review (n=7,968)
Does surgical or transcatheter mitral valve repair have acceptable mortality and morbidity rates in octogenarians?
Absolute Event Rate: 2.6% vs 1.4%
Octogenarians undergoing surgical or transcatheter mitral valve repair experience acceptable short-term mortality and morbidity, suggesting age alone should not be a contraindication.
Acceptable short-term mortality supports SMVr or TMVr in octogenarians; reinforces age alone should not preclude repair.
BACKGROUND: Valvular heart disease (VHD) is a prominent problem in healthcare today with mitral regurgitation (MR) being the leading cause of VHD in the elderly population. While mitral valve repair (MVr) surgery is one of the only options for the end-stage disease, octogenarians are often denied MVr due to concerns with operative mortality and postoperative morbidity. To provide information on this underrepresented group of surgical patients, a systematic approach was taken to review the mortality and morbidity rates of octogenarians who received MVr. METHODS: Pubmed and Medline were searched for articles containing outcomes of octogenarians receiving surgical mitral valve repair (SMVr) or transcatheter mitral valve repair (TMVr) published after 2000. Ten articles met the inclusion criteria for a total of 7968 patients included in the analysis using Microsoft Excel, Version 2105. RESULTS: Short-term mortality rates for SMVr and TMVr were 2.6% and 1.4% for in-hospital, and 7.8% and 3.3% for 30 days, respectively. The average incidence of stroke, acute kidney injury, infection, and major bleeding for SMVr were 3.2%, 11.2%, 7.7%, and 24%, respectively, and 0.3%, 6.7%, 2.7%, and 7.9% for TMVr, respectively. CONCLUSION: Octogenarians receiving SMVr or TMVr experienced similar rates of short-term mortality and morbidity as younger populations, and when considering life expectancy, midterm mortality was also similar. With these results, denying octogenarians MVr operations based on age alone should be reconsidered. Depending on risk factors and comorbidities, either SMVr or TMVr is a viable and relatively safe option for octogenarians with severe MR.
No takes yet. Share an insight, caveat, or question.
Watkins et al. (2022) conducted a systematic review in Mitral regurgitation (n=7,968). Surgical mitral valve repair (SMVr) vs. Transcatheter mitral valve repair (TMVr) was evaluated on In-hospital mortality. Surgical and transcatheter mitral valve repair in octogenarians demonstrated in-hospital mortality rates of 2.6% and 1.4%, and 30-day mortality rates of 7.8% and 3.3%, respectively.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: